Kite Pharma Stock Price, News & Analysis (NASDAQ:KITE)

$179.99 0.20 (0.11 %)
(As of 01/16/2018 12:52 PM ET)
Previous Close$179.79
Today's Range$179.99 - $179.99
52-Week Range$39.82 - $179.99
Volume100 shs
Average Volume1.65 million shs
Market Capitalization$10.28 billion
P/E Ratio-26.09
Dividend YieldN/A
BetaN/A

About Kite Pharma (NASDAQ:KITE)

Kite Pharma logoKite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Receive KITE News and Ratings via Email

Sign-up to receive the latest news and ratings for KITE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:KITE
CUSIPN/A
Phone+1-310-8249999

Debt

Debt-to-Equity RatioN/A
Current Ratio9.01%
Quick Ratio9.01%

Price-To-Earnings

Trailing P/E Ratio-26.0855072463768
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($6.90)
Net IncomeN/A
Net Margins-1,092.54%
Return on Equity-59.15%
Return on Assets-48.12%

Miscellaneous

Employees447
Outstanding Shares57,370,000

Kite Pharma (NASDAQ:KITE) Frequently Asked Questions

What is Kite Pharma's stock symbol?

Kite Pharma trades on the NASDAQ under the ticker symbol "KITE."

How were Kite Pharma's earnings last quarter?

Kite Pharma Inc (NASDAQ:KITE) issued its earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.75) by $0.05. The biopharmaceutical company had revenue of $4.90 million for the quarter, compared to analysts' expectations of $5.74 million. Kite Pharma had a negative net margin of 1,092.54% and a negative return on equity of 59.15%. The firm's quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.54) EPS. View Kite Pharma's Earnings History.

Where is Kite Pharma's stock going? Where will Kite Pharma's stock price be in 2018?

17 brokers have issued 12-month price targets for Kite Pharma's stock. Their forecasts range from $54.00 to $135.00. On average, they anticipate Kite Pharma's share price to reach $93.20 in the next twelve months. View Analyst Ratings for Kite Pharma.

What are Wall Street analysts saying about Kite Pharma stock?

Here are some recent quotes from research analysts about Kite Pharma stock:

  • 1. Cowen Inc analysts commented, "Competitor Novartis is scheduled to present pivotal data from CTL019’s JULIET trial in." (6/7/2017)
  • 2. Jefferies Group LLC analysts commented, "The NHS published a mock technology appraisal analysis to assess the value of CAR T therapy and determine a value-based price. The study was conducted for young ALL and determined a price of ??530K ($649K) was justified. We view this price as an upper limit for Axi-Cel pricing, and raise our Axi-Cel price estimate to $300K (prev' $200K). We also decreased WACC to 13% (prev 15%) which was offset by moderating share to drive our new PT of $101." (3/16/2017)
  • 3. Canaccord Genuity analysts commented, "The Kochenderfer study for CAR-19 published in the Journal of Clinical Oncology showed 12 months' median duration of complete response, suggesting positive read-through generally speaking for ZUMA-1. Importantly, 11 of 12 complete responses (CRs) are still ongoing, suggesting the potential for very long-term remission. We believe the CAR-19 data suggest that KTE-C19 is a favorable option for NHL patients with few, if any, other treatment options, which may provide long-term potentially curative benefit." (3/15/2017)
  • 4. Wedbush analysts commented, "KITE is poised to complete submission of the first BLA for a CAR-T therapy, but we believe slow adoption of the new treatment modality may blunt its first mover advantage, as CAR-T competition matures and treatment strategies evolve to address safety and efficacy challenges." (2/1/2017)

Who are some of Kite Pharma's key competitors?

Who are Kite Pharma's key executives?

Kite Pharma's management team includes the folowing people:

  • Arie S. Belldegrun, Executive Chairman of the Board, President, Chief Executive Officer, Founder
  • Paul L. Jenkinson, Chief Financial Officer
  • Cynthia M. Butitta, Chief Operating Officer
  • David Chang M.D. Ph.D., Executive Vice President - Research and Development, Chief Medical Officer
  • Helen S. Kim, Executive Vice President - Business Development
  • Timothy L. Moore, Executive Vice President - Technical Operations
  • Christine Cassiano, Senior Vice President - Corporate Communications and Investor Relations
  • , Bio & Compensation - 
  • Jian Irish Ph.D., Senior Vice President - Supply Chain
  • , Bio & Compensation - 
  • Jeffrey Wiezorek M.D., Senior Vice President - Clinical Development
  • Shawn Cline Tomasello, Chief Commercial Officer

How do I buy Kite Pharma stock?

Shares of Kite Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kite Pharma's stock price today?

One share of Kite Pharma stock can currently be purchased for approximately $179.99.

How big of a company is Kite Pharma?

Kite Pharma has a market capitalization of $10.28 billion. Kite Pharma employs 447 workers across the globe.

How can I contact Kite Pharma?

Kite Pharma's mailing address is 2225 Colorado Ave, SANTA MONICA, CA 90404-3505, United States. The biopharmaceutical company can be reached via phone at +1-310-8249999.


MarketBeat Community Rating for Kite Pharma (KITE)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  612 (Vote Outperform)
Underperform Votes:  275 (Vote Underperform)
Total Votes:  887
MarketBeat's community ratings are surveys of what our community members think about Kite Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kite Pharma (NASDAQ:KITE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.412.412.412.53
Ratings Breakdown: 0 Sell Rating(s)
10 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $93.20$93.20$93.20$87.25
Price Target Upside: 47.66% downside47.66% downside47.66% downside16.63% downside

Kite Pharma (NASDAQ:KITE) Consensus Price Target History

Price Target History for Kite Pharma (NASDAQ:KITE)

Kite Pharma (NASDAQ:KITE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/29/2017WedbushUpgradeUnderperform -> NeutralLowView Rating Details
8/29/2017Canaccord GenuityDowngradeBuy -> HoldLowView Rating Details
8/28/2017GuggenheimDowngradeBuy -> Neutral$128.00LowView Rating Details
8/28/2017SunTrust BanksDowngradeBuy -> HoldMediumView Rating Details
8/28/2017BTIG ResearchDowngradeBuy -> NeutralHighView Rating Details
8/10/2017Stifel NicolausReiterated RatingHold$74.00LowView Rating Details
8/9/2017Jefferies GroupReiterated RatingBuy$121.00 -> $135.00LowView Rating Details
7/13/2017Maxim GroupDowngradeBuy -> Hold$88.00LowView Rating Details
7/4/2017Roth CapitalReiterated RatingBuy$93.00MediumView Rating Details
7/4/2017CowenReiterated RatingOutperformMediumView Rating Details
5/30/2017FBR & CoReiterated RatingBuyLowView Rating Details
5/19/2017HC WainwrightReiterated RatingBuy$85.00MediumView Rating Details
5/15/2017Raymond James FinancialDowngradeOutperform -> Mkt PerformN/AView Rating Details
5/9/2017Goldman Sachs GroupBoost Price TargetBuy$85.00 -> $89.00HighView Rating Details
3/13/2017Standpoint ResearchDowngradeBuy -> Hold$85.00LowView Rating Details
3/6/2017Royal Bank of CanadaBoost Price TargetOutperform$85.00 -> $95.00N/AView Rating Details
3/2/2017CitigroupDowngradeBuy -> Neutral$62.00 -> $87.00N/AView Rating Details
2/22/2017Wells Fargo & CoInitiated CoverageMarket Perform -> Market PerformN/AView Rating Details
9/27/2016BarclaysBoost Price TargetEqual Weight$60.00 -> $65.00N/AView Rating Details
8/9/2016MizuhoSet Price TargetBuy$80.00N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Kite Pharma (NASDAQ:KITE) Earnings History and Estimates Chart

Earnings by Quarter for Kite Pharma (NASDAQ:KITE)

Kite Pharma (NASDAQ KITE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($1.97)($1.94)$9.59 million$10.10 millionViewListenView Earnings Details
5/8/2017Q1 2017($1.68)($1.74)$8.85 million$9.80 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.75)($1.70)$5.74 million$4.90 millionViewListenView Earnings Details
11/9/2016Q316($1.68)($1.49)$4.94 million$7.34 millionViewListenView Earnings Details
8/8/2016Q216($1.21)($0.91)$4.86 million$4.80 millionViewN/AView Earnings Details
5/9/2016Q116($1.08)($0.90)$4.61 million$5.10 millionViewN/AView Earnings Details
2/29/2016Q4($0.71)($0.85)$4.54 million$4.89 millionViewListenView Earnings Details
11/12/2015Q315($0.64)($0.63)$4.06 million$5.10 millionViewListenView Earnings Details
8/10/2015Q215($0.41)($0.48)$2.51 million$4.40 millionViewListenView Earnings Details
5/15/2015Q115$1.16($0.36)$19.70 million$2.90 millionViewN/AView Earnings Details
3/26/2015Q414($0.16)($0.33)ViewN/AView Earnings Details
11/14/2014Q314($0.23)($0.24)ViewN/AView Earnings Details
8/14/2014Q2 2014($0.06)($0.61)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Kite Pharma (NASDAQ:KITE) Earnings Estimates

2018 EPS Consensus Estimate: ($7.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($2.26)($1.89)($2.08)
Q2 20182($2.26)($1.74)($2.00)
Q3 20182($2.21)($1.81)($2.01)
Q4 20182($1.96)($1.80)($1.88)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Kite Pharma (NASDAQ:KITE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Kite Pharma (NASDAQ KITE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.00%
Institutional Ownership Percentage: 87.72%
Insider Trades by Quarter for Kite Pharma (NASDAQ:KITE)
Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)

Kite Pharma (NASDAQ KITE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/25/2017Arie BelldegrunChairmanSell26,347$179.66$4,733,502.02135,507View SEC Filing  
9/25/2017Cynthia M ButittaCOOSell4,228$179.66$759,602.48125,795View SEC Filing  
9/25/2017David D. ChangEVPSell7,927$179.66$1,424,164.82View SEC Filing  
9/25/2017Jeffrey WiezorekSVPSell5,283$179.66$949,143.78View SEC Filing  
9/25/2017Paul L. JenkinsonCFOSell948$179.66$170,317.68View SEC Filing  
9/25/2017Shawn TomaselloInsiderSell4,203$179.66$755,110.98View SEC Filing  
8/10/2017Cynthia M ButittaCOOSell15,000$120.72$1,810,800.00132,795View SEC Filing  
8/10/2017Helen Susan KimEVPSell6,251$120.09$750,682.5922,259View SEC Filing  
8/8/2017Helen Susan KimEVPSell79,949$119.56$9,558,702.4498,613View SEC Filing  
8/3/2017Timothy L MooreEVPSell6,000$110.06$660,360.0055,400View SEC Filing  
8/1/2017Timothy L MooreEVPSell12,000$107.69$1,292,280.0061,400View SEC Filing  
7/31/2017Helen Susan KimEVPSell26,649$109.28$2,912,202.7228,763View SEC Filing  
7/10/2017Cynthia M ButittaCOOSell15,000$103.09$1,546,350.00132,795View SEC Filing  
7/3/2017Jeffrey WiezorekSVPSell10,000$104.32$1,043,200.0031,071View SEC Filing  
6/26/2017Owen N WitteDirectorSell25,000$100.30$2,507,500.0098,750View SEC Filing  
6/23/2017Cynthia M ButittaCOOSell5,000$100.81$504,050.00114,845View SEC Filing  
6/16/2017Farah ChampsiDirectorSell20,450$89.79$1,836,205.50View SEC Filing  
6/14/2017Steven B RuchefskyDirectorSell20,000$89.48$1,789,600.00205,426View SEC Filing  
6/9/2017Cynthia M ButittaCOOSell10,000$88.55$885,500.00127,795View SEC Filing  
6/8/2017Roy DoumaniDirectorSell15,000$84.48$1,267,200.00155,017View SEC Filing  
5/10/2017Paul L. JenkinsonCFOBuy3,450$72.59$250,435.50View SEC Filing  
5/9/2017Arie BelldegrunChairmanBuy17,000$68.57$1,165,690.0085,507View SEC Filing  
5/9/2017David BondermanDirectorBuy50,000$68.94$3,447,000.001,950View SEC Filing  
5/1/2017David D ChangEVPSell20,000$82.09$1,641,800.0070,165View SEC Filing  
4/28/2017Farah ChampsiDirectorSell19,168$82.75$1,586,152.0079,152View SEC Filing  
4/26/2017Farah ChampsiDirectorSell123,913$82.67$10,243,887.7179,152View SEC Filing  
4/25/2017Cynthia M ButittaCOOSell15,000$81.85$1,227,750.00132,795View SEC Filing  
4/25/2017Farah ChampsiDirectorSell46,783$82.80$3,873,632.4079,152View SEC Filing  
4/24/2017Farah ChampsiDirectorSell25,818$82.34$2,125,854.1279,152View SEC Filing  
4/17/2017Farah ChampsiDirectorSell115,376$82.42$9,509,289.92View SEC Filing  
4/3/2017Cynthia M ButittaCOOSell5,000$81.96$409,800.00122,795View SEC Filing  
4/3/2017Helen Susan KimEVPSell2,400$81.80$196,320.0021,064View SEC Filing  
3/27/2017Cynthia M ButittaCOOSell10,000$77.67$776,700.00127,795View SEC Filing  
3/15/2017Timothy L MooreEVPSell7,511$83.31$625,741.4141,889View SEC Filing  
3/9/2017Cynthia M ButittaCOOSell21,118$80.78$1,705,912.04138,913View SEC Filing  
3/1/2017Cynthia M ButittaCOOSell38,882$73.46$2,856,271.72127,795View SEC Filing  
3/1/2017Helen Susan KimEVPSell50,300$67.78$3,409,334.0050,265View SEC Filing  
3/1/2017Jeffrey WiezorekSVPSell18,000$75.01$1,350,180.00View SEC Filing  
3/1/2017Roy DoumaniDirectorSell18,800$74.46$1,399,848.00121,017View SEC Filing  
2/27/2017Cynthia M ButittaCOOSell10,000$54.42$544,200.00127,795View SEC Filing  
1/31/2017Cynthia M ButittaCOOSell10,000$50.56$505,600.00127,795View SEC Filing  
1/6/2017Cynthia M ButittaCOOSell10,000$50.13$501,300.00127,795View SEC Filing  
1/6/2017Jeffrey WiezorekSVPSell1,500$50.00$75,000.0022,195View SEC Filing  
12/20/2016Arie BelldegrunChairmanSell3,493$50.86$177,653.9824,707View SEC Filing  
12/20/2016Cynthia M ButittaCOOSell2,482$50.86$126,234.5292,995View SEC Filing  
12/20/2016David D. ChangEVPSell1,788$50.86$90,937.68View SEC Filing  
12/20/2016Jeffrey WiezorekSVPSell716$50.86$36,415.7615,095View SEC Filing  
12/20/2016Shawn TomaselloInsiderSell4,901$50.86$249,264.86View SEC Filing  
12/1/2016Jeffrey WiezorekSVPSell1,500$50.76$76,140.0017,311View SEC Filing  
11/25/2016Cynthia M ButittaCOOSell10,000$50.40$504,000.00105,477View SEC Filing  
10/3/2016Jeffrey WiezorekSVPSell1,500$54.81$82,215.0017,311View SEC Filing  
9/26/2016Cynthia M ButittaCOOSell10,000$54.13$541,300.00105,477View SEC Filing  
9/1/2016Jeffrey WiezorekSVPSell1,500$58.24$87,360.00View SEC Filing  
8/25/2016Cynthia M. ButittaCOOSell10,000$58.28$582,800.00View SEC Filing  
8/15/2016Helen Susan KimEVPSell35,900$60.27$2,163,693.0042,500View SEC Filing  
8/1/2016Jeffrey WiezorekSVPSell1,500$56.90$85,350.0016,367View SEC Filing  
7/25/2016Cynthia M ButittaCOOSell10,000$50.94$509,400.00105,401View SEC Filing  
7/1/2016Jeffrey WiezorekSVPSell1,500$50.00$75,000.0016,367View SEC Filing  
6/27/2016Cynthia M ButittaCOOSell20,000$50.71$1,014,200.00105,401View SEC Filing  
6/6/2016Roy DoumaniDirectorSell10,000$57.91$579,100.00136,017View SEC Filing  
6/1/2016Jeffrey WiezorekSVPSell3,000$50.65$151,950.0016,367View SEC Filing  
4/4/2016Cynthia M ButittaCFOSell10,000$50.00$500,000.00105,401View SEC Filing  
3/15/2016Jeffrey WiezorekSVPSell9,000$44.88$403,920.0023,867View SEC Filing  
3/15/2016Margo R RobertsInsiderSell8,506$45.23$384,726.3818,155View SEC Filing  
3/15/2016Rizwana F SprouleVPSell8,500$45.27$384,795.0018,711View SEC Filing  
3/1/2016Cynthia M. ButittaCFOSell10,000$50.03$500,300.00105,401View SEC Filing  
2/17/2016Margo R. RobertsinsiderSell9,632$45.06$434,017.929,098View SEC Filing  
2/17/2016Rizwana F. SprouleVPSell9,567$45.08$431,280.368,741View SEC Filing  
2/12/2016Margo R. RobertsinsiderSell18,750$64.16$1,203,000.009,098View SEC Filing  
2/2/2016Cynthia M. ButittaCFOSell1,900$50.13$95,247.0094,007View SEC Filing  
2/1/2016Marc BetterVPSell9,000$47.34$426,060.007,688View SEC Filing  
1/27/2016Cynthia M. ButittaCFOSell8,100$51.62$418,122.0094,007View SEC Filing  
1/19/2016Rizwana F. SprouleVPSell9,567$55.49$530,872.838,741View SEC Filing  
1/15/2016Jeffrey WiezorekSVPSell9,000$55.26$497,340.0013,742View SEC Filing  
1/15/2016Margo R. RobertsinsiderSell6,145$55.22$339,326.909,098View SEC Filing  
1/4/2016Marc BetterVPSell9,000$61.53$553,770.007,688View SEC Filing  
12/28/2015Cynthia M. ButittaCFOSell10,000$61.56$615,600.0094,007View SEC Filing  
11/27/2015Cynthia M. ButittaCFOSell15,000$86.45$1,296,750.0075,507View SEC Filing  
11/16/2015Jeffrey WiezorekSVPSell9,000$78.08$702,720.006,342View SEC Filing  
11/16/2015Margo R. RobertsinsiderSell6,145$78.16$480,293.202,198View SEC Filing  
11/16/2015Rizwana F. SprouleVPSell9,567$78.13$747,469.712,941View SEC Filing  
11/2/2015David D. ChangEVPSell7,700$71.08$547,316.006,904View SEC Filing  
11/2/2015Marc BetterVPSell9,000$71.07$639,630.001,888View SEC Filing  
10/27/2015Cynthia M. ButittaCFOSell10,000$69.91$699,100.0075,507View SEC Filing  
10/15/2015Jeffrey WiezorekSVPSell9,000$62.59$563,310.006,342View SEC Filing  
10/15/2015Margo R. RobertsinsiderSell6,145$62.57$384,492.652,198View SEC Filing  
10/15/2015Rizwana F. SprouleVPSell9,567$62.58$598,702.862,941View SEC Filing  
10/1/2015David D. ChangEVPSell7,700$55.11$424,347.006,904View SEC Filing  
10/1/2015Marc BetterVPSell9,000$54.81$493,290.001,888View SEC Filing  
9/28/2015Cynthia M. ButittaCFOSell10,000$55.87$558,700.0075,507View SEC Filing  
9/15/2015Margo R. RobertsinsiderSell6,145$64.33$395,307.852,198View SEC Filing  
9/15/2015Rizwana F. SprouleVPSell9,567$64.36$615,732.122,941View SEC Filing  
9/8/2015David D. ChangEVPSell7,700$55.00$423,500.006,904View SEC Filing  
9/1/2015Marc BetterVPSell9,000$51.81$466,290.001,888View SEC Filing  
8/27/2015Cynthia M. ButittaCFOSell10,000$53.62$536,200.0075,507View SEC Filing  
8/17/2015Jeffrey WiezorekVPSell9,000$60.87$547,830.00View SEC Filing  
8/17/2015Margo R RobertsInsiderSell6,145$60.90$374,230.50View SEC Filing  
7/1/2015David D ChangEVPSell7,700$61.92$476,784.00View SEC Filing  
7/1/2015Marc BetterVPSell9,000$61.90$557,100.00View SEC Filing  
6/29/2015Cynthia M ButittaCFOSell10,000$59.65$596,500.00View SEC Filing  
6/25/2015Jeffrey WiezorekVPBuy4,000$17.00$68,000.00View SEC Filing  
6/15/2015David D ChangEVPSell7,700$56.98$438,746.00View SEC Filing  
6/15/2015Margo R RobertsInsiderSell8,625$56.99$491,538.75View SEC Filing  
6/15/2015Rizwana F SprouleVPSell9,567$56.98$545,127.66View SEC Filing  
6/2/2015Ran NussbaumDirectorSell305,434$55.35$16,905,771.90View SEC Filing  
6/1/2015Marc BetterVPSell9,000$54.60$491,400.00View SEC Filing  
6/1/2015Ran NussbaumDirectorSell80,760$55.34$4,469,258.40View SEC Filing  
4/27/2015Cynthia M ButittaCFOSell10,000$59.76$597,600.00View SEC Filing  
3/30/2015Ran NussbaumDirectorSell193,730$60.45$11,710,978.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Kite Pharma (NASDAQ KITE) News Headlines

Source:
DateHeadline
Can Biotech Keep Last Years Momentum Alive in 2018? - NasdaqCan Biotech Keep Last Year's Momentum Alive in 2018? - Nasdaq
www.nasdaq.com - January 11 at 3:33 PM
Can Biotech Keep Last Years Momentum Alive in 2018?Can Biotech Keep Last Year's Momentum Alive in 2018?
www.zacks.com - January 11 at 10:58 AM
Bolder Novo Nordisk Emerges With $3.1 Billion Ablynx Pursuit - BloombergBolder Novo Nordisk Emerges With $3.1 Billion Ablynx Pursuit - Bloomberg
www.bloomberg.com - January 9 at 3:32 PM
UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer - GlobeNewswire (press release)UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer - GlobeNewswire (press release)
globenewswire.com - January 9 at 3:32 PM
Why 2017 Was a Year to Remember for Gilead Sciences, Inc. - Motley FoolWhy 2017 Was a Year to Remember for Gilead Sciences, Inc. - Motley Fool
www.fool.com - January 5 at 3:33 PM
2018 Biotech preview: The biotech industry aims to find solutions for the worst maladies - San Francisco Business Times2018 Biotech preview: The biotech industry aims to find solutions for the worst maladies - San Francisco Business Times
www.bizjournals.com - January 4 at 3:32 PM
Gilead Might Want To Consider Selling Its HCV Drug Business To China - Seeking AlphaGilead Might Want To Consider Selling Its HCV Drug Business To China - Seeking Alpha
seekingalpha.com - January 2 at 8:45 PM
The Intrinsic Value Of Gilead ScienceThe Intrinsic Value Of Gilead Science
www.forbes.com - January 1 at 3:32 PM
What The Cell Design Labs Acquisition Means For Gilead? - Seeking AlphaWhat The Cell Design Labs Acquisition Means For Gilead? - Seeking Alpha
seekingalpha.com - December 18 at 3:31 PM
Financial Contrast: Kite Pharma (KITE) and Its PeersFinancial Contrast: Kite Pharma (KITE) and Its Peers
www.americanbankingnews.com - December 16 at 5:16 AM
CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & MoreCAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More
www.zacks.com - December 15 at 3:35 PM
Dont Count on Gilead Buying GalapagosDon't Count on Gilead Buying Galapagos
finance.yahoo.com - December 15 at 3:35 PM
Contrasting Kite Pharma (KITE) & Its CompetitorsContrasting Kite Pharma (KITE) & Its Competitors
www.americanbankingnews.com - December 13 at 8:54 AM
Kite Pharma (KITE) vs. Its Rivals Head-To-Head SurveyKite Pharma (KITE) vs. Its Rivals Head-To-Head Survey
www.americanbankingnews.com - December 10 at 3:30 PM
REFILE-Gilead to buy Cell Design Labs for up to $567 millionREFILE-Gilead to buy Cell Design Labs for up to $567 million
www.reuters.com - December 9 at 3:33 PM
UPDATE 1-Gilead to buy Cell Design Labs for up to $567 mlnUPDATE 1-Gilead to buy Cell Design Labs for up to $567 mln
www.businessinsider.com - December 9 at 3:33 PM
Gilead Sciences to Acquire Cell Design Labs for $567 Million - Yahoo FinanceGilead Sciences to Acquire Cell Design Labs for $567 Million - Yahoo Finance
finance.yahoo.com - December 8 at 3:31 PM
Gilead Sciences: Look Whos Shopping!Gilead Sciences: Look Who's Shopping!
finance.yahoo.com - December 8 at 3:31 PM
Gilead Sciences to buy Cell Design Labs for $567 million - MarketWatchGilead Sciences to buy Cell Design Labs for $567 million - MarketWatch
www.marketwatch.com - December 8 at 10:37 AM
Biotech Eyes Tax Revamp as Next Chance to Shake Its Recent WoesBiotech Eyes Tax Revamp as Next Chance to Shake Its Recent Woes
www.bloomberg.com - December 1 at 3:39 PM
Gene Therapy Is Booming, But How Will We Manage The Costs?Gene Therapy Is Booming, But How Will We Manage The Costs?
finance.yahoo.com - December 1 at 3:39 PM
Analyzing Kite Pharma (KITE) and Its CompetitorsAnalyzing Kite Pharma (KITE) and Its Competitors
www.americanbankingnews.com - November 30 at 9:32 PM
Does Gilead's Kite Acquisition Offer A New Buying Opportunity?Does Gilead's Kite Acquisition Offer A New Buying Opportunity?
finance.yahoo.com - November 30 at 3:31 PM
Gilead Sciences: Are You Willing To Wait 3 Years? - Seeking AlphaGilead Sciences: Are You Willing To Wait 3 Years? - Seeking Alpha
seekingalpha.com - November 28 at 3:30 PM
Buy Gilead Now And Get Kite For Free - Seeking AlphaBuy Gilead Now And Get Kite For 'Free' - Seeking Alpha
seekingalpha.com - November 28 at 3:30 PM
7 Life Science Stocks to Buy Today - Yahoo News7 Life Science Stocks to Buy Today - Yahoo News
finance.yahoo.com - November 15 at 3:51 AM
Kite Pharma Inc (KITE) Given Consensus Recommendation of "Hold" by AnalystsKite Pharma Inc (KITE) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 12 at 9:54 AM
UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors - GlobeNewswire (press release)UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors - GlobeNewswire (press release)
globenewswire.com - November 4 at 4:08 AM
Juno touts latest cancer drug results after rivals win FDA approval - Puget Sound Business Journal (Seattle)Juno touts latest cancer drug results after rivals win FDA approval - Puget Sound Business Journal (Seattle)
www.bizjournals.com - November 2 at 4:20 AM
Kite Pharma Inc (KITE) to Release Quarterly Earnings on TuesdayKite Pharma Inc (KITE) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:36 AM
UPDATE 2-Gilead weak hepatitis C sales outlook sends shares lowerUPDATE 2-Gilead weak hepatitis C sales outlook sends shares lower
www.cnbc.com - October 26 at 9:28 PM
Gilead revenue falls 13%, worst yet to comeGilead revenue falls 13%, worst yet to come
www.marketwatch.com - October 26 at 9:28 PM
BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta™ (Axicabtagene Ciloleucel) CAR T-Cell ... - PR Newswire (press release)BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta™ (Axicabtagene Ciloleucel) CAR T-Cell ... - PR Newswire (press release)
www.prnewswire.com - October 20 at 2:37 AM
The Math Behind the Gileads Recent Merger - Seeking AlphaThe Math Behind the Gilead's Recent Merger - Seeking Alpha
seekingalpha.com - October 18 at 3:40 PM
Kite Pharma, Inc. (KITE) Receives Consensus Recommendation of "Hold" from BrokeragesKite Pharma, Inc. (KITE) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 18 at 12:50 PM
Q3 Roundup: Top 5 Performing KnivesQ3 Roundup: Top 5 Performing Knives
seekingalpha.com - October 16 at 5:09 AM
Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma BuyGilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy
investorplace.com - October 13 at 10:34 AM
Immunotherapy Treatments for Cancer Gain MomentumImmunotherapy Treatments for Cancer Gain Momentum
www.msn.com - October 13 at 6:14 AM
Vertex Pharmaceuticals: Excellence In Cystic Fibrosis, Strong Potential AheadVertex Pharmaceuticals: Excellence In Cystic Fibrosis, Strong Potential Ahead
seekingalpha.com - October 10 at 7:42 PM
Form 4 Kite Pharma, Inc. For: Oct 03 Filed by: Peacock Jonathan M - StreetInsider.comForm 4 Kite Pharma, Inc. For: Oct 03 Filed by: Peacock Jonathan M - StreetInsider.com
www.streetinsider.com - October 7 at 1:36 AM
Gilead Sciences Completes Acquisition of Kite Pharma, Inc. - Business Wire (press release)Gilead Sciences Completes Acquisition of Kite Pharma, Inc. - Business Wire (press release)
www.businesswire.com - October 5 at 6:33 AM
Gilead Sciences: We Dont Think That His Departure Is a Red HerringGilead Sciences: 'We Don't Think That His Departure Is a Red Herring'
finance.yahoo.com - October 2 at 12:36 PM
Better Buy: Gilead Sciences, Inc. vs. PfizerBetter Buy: Gilead Sciences, Inc. vs. Pfizer
finance.yahoo.com - October 2 at 12:36 PM
Here's Why Bluebird Bio (BLUE) Stock Is Falling TodayHere's Why Bluebird Bio (BLUE) Stock Is Falling Today
finance.yahoo.com - October 2 at 12:36 PM
 Brokerages Anticipate Kite Pharma, Inc. (KITE) Will Announce Earnings of -$2.13 Per Share Brokerages Anticipate Kite Pharma, Inc. (KITE) Will Announce Earnings of -$2.13 Per Share
www.americanbankingnews.com - October 2 at 10:26 AM
Exclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sourcesExclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sources
www.reuters.com - September 30 at 12:13 AM
Why Biotech and Tech Will Push Stocks Higher In 4QWhy Biotech and Tech Will Push Stocks Higher In 4Q
www.investopedia.com - September 29 at 2:07 PM
Daily Technical Summary Reports on Biotech Stocks -- Gilead Sciences, Kite ...Daily Technical Summary Reports on Biotech Stocks -- Gilead Sciences, Kite ...
www.prnewswire.com - September 29 at 2:07 PM
Form 4 Kite Pharma, Inc. For: Sep 25 Filed by: Tomasello ShawnForm 4 Kite Pharma, Inc. For: Sep 25 Filed by: Tomasello Shawn
www.streetinsider.com - September 28 at 10:12 AM
Insider Selling: Kite Pharma, Inc. (KITE) CFO Sells 948 Shares of StockInsider Selling: Kite Pharma, Inc. (KITE) CFO Sells 948 Shares of Stock
www.americanbankingnews.com - September 27 at 10:32 PM

SEC Filings

Kite Pharma (NASDAQ:KITE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Kite Pharma (NASDAQ:KITE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Kite Pharma (NASDAQ KITE) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.